



AMGEN-SPONSORED SATELLITE SYMPOSIUM AT 22ND CONGRESS OF THE EAHP

What the pharmacist needs to know when selecting biosimilar monoclonal antibodies in oncology: the case of trastuzumab biosimilars

Thursday 23 March 2017, 15.00–16.30

Auditorium Louis Lumière



Arnold Vulto
(Chair)
The Netherlands



Marc Thill
Germany



Liese Barbier
Belgium

Programme

Chair: Arnold Vulto, The Netherlands

Welcome and introduction	Arnold Vulto
Selecting a biosimilar: current recommendations and future challenges	Arnold Vulto
Preparing to assess biosimilar mAbs in oncology: understanding the clinical role of trastuzumab	Marc Thill
Clinical studies for biosimilar trastuzumab in the treatment of breast cancer: similarities and differences	Liese Barbier
Call to action: panel discussion	All
Concluding comments and close	Arnold Vulto

Don't forget to join the Synergy satellite symposium '10 years of biosimilars – what have we learned?' (supported by an educational grant from Amgen) taking place on Wednesday 22 March 2017 from 11.30–13.00 in the Théâtre Claude Debussy